Navigation Links
Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/6/2012

SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter and year ended December 31, 2011.

  • Total revenue for the quarter ended December 31, 2011 was $164.9 million, which included net product sales of $160.9 million.
  • Non-GAAP operating income for the quarter ended December 31, 2011 was $17.6 million, compared to a non-GAAP operating income of $22.9 million for the same period in 2010.
  • Full year non-GAAP operating income was $25.7 million, compared to a non-GAAP operating loss of $4.4 million in 2010.
  • Cash, cash equivalents, short-term investments and restricted cash totaled $214.6 million at the end of the quarter.

  • "Our strong execution in 2011 has positioned us to enter 2012 with an extraordinary opportunity to maximize shareholder value. We generated positive operating cash flow, reacquired the full rights to the exenatide franchise, expanded the approved uses for BYETTA, and, most importantly, positioned ourselves well to successfully launch BYDUREON in the U.S. following its recent approval," said Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals. "We will also work to secure a new partner for exenatide outside the U.S. to advance our commitment to diabetes patients around the world, and continue to invest strategically in value-driving opportunities while continuing our focus on financial discipline."

    Highlights of Amylin's Fourth Quarter and Recent Activities

  • Received U.S. Food and Drug Administration (FDA) approval for BYDUREON™ (exenatide extended-release for injectable suspension) – the first and only once-weekly medication approved in the U.S. and the European Union for the treatment of type 2 diabetes. BYDUREON will be available in pharmacies throughout the U.S. later this month.

  • '/>"/>
    SOURCE Amylin Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
    2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
    3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
    4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
    5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
    6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
    7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
    8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
    9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
    10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
    11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... 2014  Depomed, Inc. (NASDAQ: DEPO ) ... year 2014 financial results after the market closes on Wednesday, ... call beginning at 4:30 pm EDT, 1:30 pm PDT to discuss ... by dialing 877-317-6789 ( United States ) ... available via a live webcast on the investor relations ...
    (Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Full Service ... as the new Vice President of Business Development. Peter ... years in a number of different business development positions ... These positions were primarily related to business development/sales management ... past 30 years makes him a key and strategic ...
    (Date:7/25/2014)... and Tobago , July 25, 2014 /PRNewswire/ ... Trinidad & Tobago Ministry of Health approved the ... that significantly increases the cure rate from Hepatitis ... with the genotype 1 virus. Telaprevir is available ... trade brand INCIVO®. Photo - ...
    Breaking Medicine Technology:Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3
    ... VRUS ) today announced that it will webcast ... of the Liver (EASL) on Saturday, April 2, 2011 starting ... progress on the programs that are the subject of presentations ... simultaneous webcast of this event via the internet, log on ...
    ... 25, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... confirmed that it has received a favorable decision from ... related to its ongoing patent challenge in connection with ... to market a generic version of Teva Women,s Health, ...
    Cached Medicine Technology:Pharmasset to Webcast an Investor Event From the EASL Meeting 2Pharmasset to Webcast an Investor Event From the EASL Meeting 3Watson Confirms Favorable Appeals Court Ruling on Generic SEASONIQUE® Patent Challenge 2
    (Date:7/25/2014)... The Little Gym of Houston will ... July 27 at Discovery Green in downtown Houston. The ... Pearland, Friendswood, Spring, The Woodlands, Sugarland-Missouri City, Kingwood, Bellaire ... “We’re thrilled to be attending and performing at the ... owns the Sugarland-Missouri City location. “We believe in the ...
    (Date:7/25/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Ibuprofen and Oxcarbazepine Tablets . ... of Ibuprofen and one lot of Oxcarbazepine Tablets, by American ... packaging. Oxcarbazepine is used for the treatment of certain types ... reason for the recall is that Lot #142588, Expiration Date, ...
    (Date:7/25/2014)... Ticket Down is a reliable source for cheap ... California Memorial Stadium. With the post-World Cup emotions still rolling ... the 2014 Guinness International Champions Cup have brought eight of ... representing La Liga, English Premier League, Serie A, and Superleague ... players from around the world to 12 American cities and ...
    (Date:7/25/2014)... July 25, 2014 On July ... Nuanced Media client and the nation’s number one ... employee handbooks, announced their partnership with TransAct Merchant ... a registered ISO/MSP of Chase Paymentech Solutions, LLC, ... processing industry. Companies that are members of TransAct’s ...
    (Date:7/25/2014)... Hastings and Hastings, a ... with regard to personal injury claims, announces free initial ... of legal services for those that have been injured ... or corporation. Free initial consultation services gives clients’ greater ... potential personal injury claim . It also offers ...
    Breaking Medicine News(10 mins):Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3
    ... N.Y., March 23 You went on a diet. Great. ... keeping the weight off? What are your chances of avoiding ... Chronic Disease recommends that you turn to your doctor and ... measures the concentration of your IgG antibodies against two prevalent ...
    ... Study Adds to Growing Evidence of B. Infantis 35624 ... A review by researchers at Northwestern University ... , MI) of the utility of probiotics in the ... Bifidobacterium infantis 35624 was the only probiotic strain ...
    ... Physician-Owned Hospitals, According to New Reports from ... leading provider of managed care market intelligence, ... have traditionally enabled doctors practicing in the ... these regulations may actually yield increasing challenges ...
    ... for Distinguished Service in the Field of ChemistryEMERYVILLE, ... Alternext: NBY) today announced that world-renowned scientist M. ... Scientific Advisory Board will be the recipient of ... by the American Chemical Society (ACS). Dr. ...
    ... is One of Three FDA Approvals Spanning Lilly ... and Drug Administration (FDA) has approved a new ... Eli Lilly and Company (NYSE: LLY ... drug approved by the FDA for the acute ...
    ... PARK, Kan., March 23 According to the National ... recession since December 2007 and nearly half of U.S. ... iconic Oprah Winfrey replaced her annual ,Favorite Things, holiday ... "Thriftiest Holiday Ever!"However, the $200 billion health & wellness ...
    Cached Medicine News:Health News:How to Keep the Weight Off? By Taking Gene-Eden, a New Dietary Supplement Based on Dr. Hanan Polansky's Discovery of the Cause of Many Diseases 2Health News:Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy for IBS Symptoms 2Health News:Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy for IBS Symptoms 3Health News:Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy for IBS Symptoms 4Health News:Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy for IBS Symptoms 5Health News:In Texas, Favorable Regulations for Physicians May Backfire in Light of Market Downturn 2Health News:NovaBay Pharmaceuticals' Scientific Advisor Receives American Chemical Society's Highest Award 2Health News:NovaBay Pharmaceuticals' Scientific Advisor Receives American Chemical Society's Highest Award 3Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 2Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 3Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 4Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 5Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 6Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 7Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 8Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 9Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 10Health News:Consumers Redefine Value in the Recession: Sauna Sales Prove Preventive Health Is an Essential Investment 2
    ... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
    ... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
    ... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
    ... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
    Medicine Products: